Fresenius Medical Care Azioni (NYSE: FMS)

Ultime notizie per Fresenius Medical Care (NYSE:FMS) Azioni

Fresenius Medical Care

Fresenius Medical Care is the largest dialysis company in the world, treating over 300,000 patients from roughly 3,750 clinics across the globe as of mid-2024. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market and benefits from being the world's only fully integrated dialysis business. Services account for roughly 80% of firmwide revenue, including care coordination and ancillary operations, while products account for the other roughly 20%.

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Fresenius Medical Care AG

Foremost Clean Energy Ltd. - Common stock

Foremost Clean Energy Ltd

FMS ENTERPRISES MIGUN LTD by FMS ENTERPRISES MIGUN LTD

FMS Enterprises Migun Ltd

<ul>
<li>Strategic Relationship: Agreement expands access to&nbsp;ECMO solutions for hospitals, health systems and patients in the U.S. nationwide.</li>
<li>Wide Reach: 4,350+ Premier member hospitals and health systems in the U.S. can leverage pre-negotiated terms and pricing on the&nbsp;Novalung System for ECMO.</li>
<li>Commitment to Quality Care: Reinforces company's commitment to supporting healthcare providers in their efforts to deliver high-quality critical care treatments and solutions.</li>
</ul>
BAD HOMBURG, Germany, Nov. 19, 2024 /PRNewswire/ --&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4306438-1&amp;h=482744951&amp;u=https%3A%2F%2Fwww.freseniusmedicalcare.com%2Fen%2Fhome%2F&amp;a=Fresenius+Medical+Care">Fresenius Medical Care</a>&nbsp;(FME), the world's leading provider of products and services for individuals with renal diseases, today announced its heart and lung group has been awarded a national group purchasing agreement for Mechanical Circulatory Support with Premier, Inc in the U.S. Since acquiring Xenios in 2016, Fresenius Medical Care has been dedicated to advancing heart and lung therapy. The agreement underscores FME's commitment to critical care solutions and allows Premier member hospitals and health systems, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for the Novalung System.

Biotech

News

General

Fresenius Medical Care Awarded Mechanical Circulatory Support Agreement with Premier, Inc. For The Novalung ECMO System; Agreement Expands Access To ECMO Solutions For Hospitals, Health Systems And Patients In The U.S. Nationwide

On Wednesday, Donald Trump, the Republican candidate and former president, was elected to the highest office again, marking a return to an administration. His second term is likely to impact U.S. healthcare.
Trump has been unclear about his healthcare policy goals during his campaign. Healthcare <a target="_blank" href="https://www.kff.org/health-care-in-2024-elections-apvotecast-polling/?entry=kff-analysis-of-ap-votecast-abortion-ballot-initiatives" rel="noreferrer noopener">ranked</a> lower than issues like the economy and immigration in voter concerns.
A <a target="_blank" href="https://apnews.com/article/ap-votecast-elections-harris-trump-voters-d5cf4e3611f50ec4349d93ddc7f037cd" rel="noreferrer noopener">poll</a> from the Associated Press found that only 8% of voters viewed healthcare as their top issue, compared to 39% who chose the economy and 20% who picked immigration. Abortion was the leading issue for 11% of voters.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction" rel="noreferrer noopener">Trump&#8217;s Potential &#8216;Health Czar&#8217; Robert F. Kennedy Jr. Rattles Vaccine Stocks: &#8216;Shoot First Reaction&#8217;</a>
Despite his focus on &#8220;Make America Healthy Again,&#8221; millions of Americans may lose health insurance subsidies next year, depending on the political climate after the election and the Republicans&#8217; control of the Senate.
The subsidies, expanded under the 2021 American Rescue Plan, help many, particularly the middle class, afford health insurance through the Affordable Care Act (ACA).
These subsidies are set to expire at the end of 2025, and it remains uncertain whether they will be extended under the new administration.
Trump and other Republicans have opposed continuing the subsidies.
The NBC News <a target="_blank" href="https://www.nbcnews.com/health/health-news/millions-risk-losing-health-insurance-trumps-victory-rcna179146" rel="noreferrer noopener">report</a>, citing some analysts, suggests that the chances of extension could be less than 5% if Republicans win control of the House and the Senate.
Even if Democrats control the House, extending these subsidies seems unlikely. Without an extension, nearly 4 million Americans could lose coverage by 2026 due to unaffordable premiums.
The 2021 changes led to a surge in ACA enrollment, with 15.5 million people benefiting from subsidies across 32 states. The report adds that if the subsidies aren&#8217;t renewed, up to 15.4 million Americans could lose health coverage by 2030.
Another significant issue is Trump&#8217;s stance on Medicare. As president, he supported Medicare Advantage, a private insurer-run program that could eventually replace traditional, government-run Medicare.
The NPR report <a target="_blank" href="https://www.npr.org/sections/shots-health-news/2024/11/07/nx-s1-5183092/trump-election-2024-medicare-advantage" rel="noreferrer noopener">highlights</a> that critics argue that expanding private insurers could increase costs for taxpayers and limit care, with some beneficiaries finding it difficult to switch back to traditional Medicare.
Robert Berenson, a former government official, warned that traditional Medicare could &#8220;wither on the vine.&#8221;
Medicare Advantage grew with the 2003 legislation introducing a drug benefit and expanded private insurers&#8217; role in the program. Although private plans were expected to lower costs, they have been more expensive.
The report also says that in 2023, Medicare Advantage plans cost taxpayers about 6% — or $27 billion — more than traditional Medicare, though some research suggests they offer better care.
The future of healthcare policy in the U.S. will depend on the political dynamics in Congress and Trump&#8217;s second term.
With Republicans pushing for major changes to the ACA and Medicare, experts warn of significant shifts in how Americans access and pay for healthcare in the coming years.
Read Next
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41855578/bristol-myers-squibb-leads-biopharma-recovery-with-almost-25-growth-in-market-cap-but-novo-nordisk-and-lilly-suffer-market-setbacks" target="_blank" rel="noreferrer noopener">Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks</a></li>
</ul>
Photo via Shutterstock

Government

Regulations

Health Care

Politics

Markets

ALHC

CLOV

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Laboratory Corporation Of America Holdings

Donald Trump's Second Term Could Reshape US Healthcare System, With Major Impacts on Affordable Care Act And Medicare

Earnings

Guidance

Fresenius Medical Care Also Reconfirms Its Targets To Achieve An Operating Income Margin Of 10%-14% By 2025

Fresenius Medical Care Confirms Its Outlook For Fiscal 2024 And Expects Revenue To Grow By A Low- To Mid-single Digit Percent Rate, With Operating Income To Grow By 16%-18% Versus Prior Guidance Of Growth By A Mid- To High-teens Percent Rate

Fresenius Medical Care (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMS#NYSE">FMS</a>) reported quarterly earnings of $0.73 per share which beat the analyst consensus estimate of $0.35 by 108.57 percent. This is a 28.07 percent increase over earnings of $0.57 per share from the same period last year. The company reported quarterly sales of $4.76 billion which missed the analyst consensus estimate of $4.89 billion by 2.67 percent. This is a 3.57 percent decrease over sales of $4.94 billion the same period last year.

Fresenius Medical Care Q3 2024 Adj EPS €0.73 May Not Be Comparable To €0.35 Estimate, Sales €4.76B Miss €4.89B Estimate

Truist Securities analyst David Macdonald maintains Fresenius Medical Care (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMS#NYSE">FMS</a>) with a Hold and raises the price target from $22 to $23.

Price Target

Analyst Ratings

Truist Securities Maintains Hold on Fresenius Medical Care, Raises Price Target to $23

Fresenius Medical Care (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fms#NYSE">FMS</a>) is one of the largest integrated providers of products and services for individuals undergoing dialysis following chronic kidney failure. Through its network of more than 3,600 clinics across the world, the company offers dialysis services and products in more than 120 countries and employs over 109,000 staff in more than 50 countries.
Fresenius Medical reports through two segments &mdash; Care Delivery and Care Enablement. The Care Delivery segment consists of the company&#39;s Dialysis Services and the Care-Coordination (non-dialysis laboratory services), which accounted for 79.6% of net revenues in the first half of 2024. The Care Enablement segment comprises the company&#39;s Dialysis machines, dialyzers, dialysis solutions, hemodialysis concentrates, bloodline systems, water treatment systems, dialysis drugs and other medical products. The segment accounted for 20.4% of net revenues in the same period.
FMS&#39; quarterly results are likely to continue benefiting from improving treatment volumes as well as a stabilizing labor environment in the United States. Overall price improvements also supported growth in the Care Enablement segment. Meanwhile, FMS&#39; newly implemented operating model led to operational improvements. The company&#39;s divestment of its noncore and dilutive assets looks promising as they will help it focus on its core and growing categories as well as boost its cash resources.
The company&#39;s shares have risen 1.5% year to date compared with the industry&#39;s 8.4% growth. The stock was primarily driven by top-line growth in the past couple of quarters. The S&amp;P 500 Index was up 20% in the same time frame.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/0a/80131.jpg?v=1829953905" />
Image Source: Zacks Investment Research
However, U.S. revenues continued to be hurt by FX impact. The bottom line was hurt by inflationary cost increases in energy, material and personnel.
<h2>Diversified Product Portfolio Boosts FMS&#39; Prospects</h2>
Fresenius Medical offers a wide array of Hemodialysis, Peritoneal dialysis and Acute dialysis products. To further boost the quality of life for its patients and increase their choice of available treatment options, Fresenius Medical Care remains focused on further expanding its home dialysis offerings. In 2022, the company provided around 15% of its dialysis treatments in the United States in a home setting, the same as last year. By 2025, the company has set a goal to perform 25% of all treatments in the U.S. at a patient&#39;s home.
<h2>FMS&#39; Strong Global Foothold Buoys Optimism</h2>
Fresenius Medical has a solid market hold in the regions of North America, Europe (EMEA), Asia Pacific and Latin America. To strengthen its market position, the company is resorting to various approaches, like enhancing its organic growth and making strategic and suitable acquisitions. The company also aims to align its business activities through public-private partnerships in the dialysis business for tapping into new markets in the coming quarters. In the recent past, the company entered the dialysis services market in Israel.
Fresenius Medical also expanded its dialysis services business in India by acquiring an 85% stake in Sandor Nephro Services, a dialysis group, offering dialysis treatment and other associated services, such as laboratory tests, to 308,471 patients in 3,624 dialysis clinics worldwide. In the second quarter of 2024, it witnessed strong contributions from the Asia Pacific, EMEA and Latin America, respectively.
<h2>Restructuring Initiatives Driving Savings</h2>
In October 2020, Fresenius Medical unveiled its 2025 strategy at its Capital Markets Day. This strategy is an appropriate one as it prioritizes patients&#39; needs, and the quality of care is in line with key drivers and developments for its industry. This positions Fresenius Medical&#39;s business well to deliver sustainable growth over the medium term and further. The FME25 transformation is anticipated to achieve a substantial amount of savings by 2025.
The company continues to progress with its FME25 transformation. In the second quarter, FMS generated 57 million euros in savings by implementing initiatives under its FME25 transformation program. The company targets savings in the range of 250-300 million euros by 2024-end and 650 million euros by 2025-end.
<h2>Factors Hurting FMS Stock</h2>
Fresenius Medical has numerous competitors in the field of health care services as well as the sale of dialysis products. Tough competition in the niche markets is likely to impede the company&#39;s sales opportunities and lose market share. However, per management, concerns that arise due to competition represent a low risk for the company in the short and mid-term. The company faces aggressive rivalry from HCA Holdings, DaVita HealthCare and Baxter International.
FMS faces a highly regulated environment in almost every country in which it operates. Furthermore, the company has to fulfill specific legal requirements everywhere, including the tough antitrust regulations. Violating healthcare or other regulations under public law can result in extensive legal repercussions.
<div class="chart_embed">
<h3>Fresenius Medical Care AG &amp; Co. KGaA Price</h3>
<img alt="Fresenius Medical Care AG &amp; Co. KGaA Price" src="https://staticx-tuner.zacks.com/images/charts/21/1727951270.png" style="height:251px; width:574px" title="" />
Fresenius Medical Care AG &amp; Co. KGaA price | Fresenius Medical Care AG &amp; Co. KGaA Quote
</div>
<h2>Zacks Rank &amp; Stock to Consider</h2>
Fresenius Medical Care currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are&nbsp;Universal Health Service,&nbsp;Quest Diagnostics&nbsp;and&nbsp;Baxter International, each carrying a Zacks Rank #2 (Buy).
Universal Health Service has an estimated long-term growth rate of 19%. UHS&#39; earnings surpassed estimates in each of the trailing four quarters, with the average being 14.58%.
Universal Health Service has gained 47% compared with the&nbsp;industry&#39;s&nbsp;47.7% rise so far this year.
Quest Diagnostics has an estimated long-term growth rate of 6.2%. DGX&#39;s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 3.31%.
Quest Diagnostics shares have gained 12.3% so far this year compared with the&nbsp;industry&#39;s&nbsp;19% rise.
Baxter&#39;s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 3.74%.
BAX&#39;s shares have declined 6.9% so far this year against the&nbsp;industry&#39;s&nbsp;13.3% growth.
<a href="https://www.zacks.com/stock/news/2345186/fms-stock-rides-on-diversified-portfolio-and-restructuring-initiatives?cid=CS-BENZ-FT-analyst_blog|zer_report_update-2345186">To read this article on Zacks.com click here.</a>

Earnings Beats

Large Cap

Offerings

Legal

Management

Trading Ideas

FMS Stock Rides on Diversified Portfolio and Restructuring Initiatives

Truist Securities analyst David Macdonald maintains Fresenius Medical Care (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMS#NYSE">FMS</a>) with a Hold and lowers the price target from $24 to $22.

Truist Securities Maintains Hold on Fresenius Medical Care, Lowers Price Target to $22

Shares of Merck &amp; Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) fell sharply during Tuesday's session after the company reported second-quarter financial results and cut its FY24 adjusted EPS <a href="https://www.benzinga.com/general/biotech/24/07/40036607/mercks-q2-earnings-revenue-and-eps-beat-helped-by-strong-keytruda-sales-but-acquisition-costs-bit">guidance below estimates</a>.
Merck reported second-quarter sales of $16.1 billion, up 7% year-over-year, beating the consensus estimate of $15.84 billion. Excluding the impact of foreign exchange, sales increased 11%. Merck reported adjusted EPS of $2.28, a shift from an EPS loss of $(2.06), beating the consensus of $2.15, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Merck shares dipped 9.5% to $115.50 on Tuesday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Imunon, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) shares jumped 147.8% to $2.9250 after the company announced topline results from its Phase 2 OVATION 2 study with IMNN-001. The results showed an 11.1-month improvement in median overall survival compared to standard-of-care alone in the intent-to-treat population.</li>
<li>Agape ATP Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) surged 97% to $0.1731. AGAPE ATP strengthened wellness division via innovative incubation with emerging local SMEs.</li>
<li>Processa Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCSA#NASDAQ">PCSA</a>) shares climbed 53% to $2.60 after the company announced FDA clearance of its IND application for a Phase 2 clinical trial of NGC-Cap in breast cancer.</li>
<li>INVO Bioscience, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVO#NASDAQ">INVO</a>) gained 33% to $1.1513.</li>
<li>Jet.AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JTAI#NASDAQ">JTAI</a>) shares gained 29% to $0.3850.</li>
<li>2U, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWOU#NASDAQ">TWOU</a>) jumped 28% to $3.4018.</li>
<li>CalciMedica, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALC#NASDAQ">CALC</a>) jumped 26.3% to $5.24.</li>
<li>JetBlue Airways Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NASDAQ">JBLU</a>) rose 20.6% to $7.16 after the company reported better-than-expected second-quarter financial results.</li>
<li>Lumen Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>) rose 19.1% to $2.3050.</li>
<li>Commvault Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVLT#NASDAQ">CVLT</a>) gained 19.1% to $146.77 after the company reported better-than-expected first-quarter financial results and issued second-quarter revenue guidance above estimates. Also, the company raised its FY25 revenue guidance.</li>
<li>Harmonic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLIT#NASDAQ">HLIT</a>) climbed 18.8% to $13.96 after the company reported better-than-expected second-quarter financial results and issued third-quarter revenue guidance above estimates.</li>
<li>Meta Data Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIU#NYSE">AIU</a>) gained 18.8% to $5.42.</li>
<li>Enveric Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVB#NASDAQ">ENVB</a>) rose 18.3% to $0.59 after jumping around 6% on Monday.</li>
<li>Inspirato Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPO#NASDAQ">ISPO</a>) gained 18.3% to $6.20 after jumping over 50% on Monday.</li>
<li>Sprouts Farmers Market, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFM#NASDAQ">SFM</a>) shares gained 15.9% to $98.13 after the company reported better-than-expected second-quarter financial results and issued its third-quarter earnings guidance above estimates.</li>
<li>NeoGenomics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) gained 16.1% to $17.00 following upbeat earnings.</li>
<li>Tilray Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) rose 16.1% to $2.1250 after the company reported better-than-expected quarterly financial results.</li>
<li>Sprouts Farmers Market, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFM#NASDAQ">SFM</a>) gained 15.5% to $97.79 after the company reported better-than-expected second-quarter financial results. Additionally, the company issued third-quarter earnings guidance above estimates.</li>
<li>Howmet Aerospace Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HWM#NYSE">HWM</a>) climbed 14.1% to $94.56 following better-than-expected second-quarter earnings, issued strong guidance, raised its dividend, increased its buyback authorization and issued strong guidance.</li>
<li>Repligen Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) gained 13.4% to $156.48 following -quarter earnings.</li>
<li>Varonis Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNS#NASDAQ">VRNS</a>) climbed 13.3% to $54.92 as the company reported better-than-expected second-quarter financial results and raised its FY24 guidance on Monday.</li>
<li>Hayward Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAYW#NYSE">HAYW</a>) gained 11% to $14.98 after the company reported better-than-expected second-quarter EPS results.</li>
<li>F5, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIV#NASDAQ">FFIV</a>) shares rose 10.6% to $196.46 after the company reported better-than-expected third-quarter financial results and raised its FY24 earnings guidance above estimates.</li>
<li>Pharming Group N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHAR#NASDAQ">PHAR</a>) shares gained 9.8% to $8.28. Pharming Group will report second quarter financial results on Aug. 1.</li>
<li>PayPal Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) climbed 8.5% to $63.98 after the company reported better-than-expected second quarter financial results.</li>
<li>Stanley Black &amp; Decker, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWK#NYSE">SWK</a>) rose 8.1% to $104.28 after the company reported better-than-expected second quarter financial results. Additionally, the company revised its FY24 adjusted EPS forecast upward.</li>
<li>Gartner, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IT#NYSE">IT</a>) gained 6.4% to $500.83 following better-than-expected quarterly earnings.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>QXO, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NASDAQ">QXO</a>) shares fell 80.8% to $11.44. This sudden decline was triggered by the registration of two private placements with the U.S. Securities and Exchange Commission, which unlocked millions of shares and led to increased selling pressure, Bloomberg reported on Tuesday.</li>
<li>VBI Vaccines Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VBIV#NASDAQ">VBIV</a>) declined 64.8% to $0.1960 after the company was granted protection under Canada&#8217;s CCAA by the Ontario Superior Court. The company received approval for a DIP loan, and Ernst &amp; Young was appointed as the monitor during the restructuring process.</li>
<li>CNS Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) dipped 40.8% to $0.6158 after the company announced it entered into an exclusive license agreement with Cortice Biosciences.</li>
<li>BIMI Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIMI#NASDAQ">BIMI</a>) tumbled 37% to $0.73.</li>
<li>Bloomz Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMZ#NASDAQ">BLMZ</a>) dipped 30.7% to $1.78.</li>
<li>Ekso Bionics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EKSO#NASDAQ">EKSO</a>) fell 26.6% to $1.0901 after the company reported worse-than-expected quarterly sales results.</li>
<li>Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) shares declined 25.2% to $12.27 after declining 4% on Monday.</li>
<li>VSee Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSEE#NASDAQ">VSEE</a>) fell 23.3% to $2.7999.</li>
<li>SmartRent, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMRT#NYSE">SMRT</a>) dipped 21.5% to $1.8850 after the company announced a CEO resignation and suspended its 2024 outlook.</li>
<li>Symbotic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NASDAQ">SYM</a>) shares fell 21.1% to $28.13 after the company reported worse-than-expected third-quarter earnings results and issued fourth-quarter revenue guidance below estimates.</li>
<li>Woodward, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WWD#NASDAQ">WWD</a>) fell 16.5% to $152.91 after the company reported mixed third-quarter financial results and lowered its FY24 revenue guidance below estimates.</li>
<li>NIP Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIPG#NASDAQ">NIPG</a>) fell 16.2% to $13.82. NIP Group announced the closing of its initial public offering and partial exercise of underwriters' option to purchase additional ADSs.</li>
<li>Merchants Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIN#NASDAQ">MBIN</a>) dipped 16.2% to $43.68 after the company reported worse-than-expected quarterly financial results. Additionally, Raymond James downgraded the stock.</li>
<li>Amkor Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMKR#NASDAQ">AMKR</a>) shares fell 14.2% to $32.24 after the company issued roughly in-line guidance.</li>
<li>OneWater Marine Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONEW#NASDAQ">ONEW</a>) dipped 13.2% to $26.43 after the company reported worse-than-expected third-quarter financial results and issued weak guidance.</li>
<li>Celldex Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) shares fell 11.6% to $37.06 after reporting Phase 2 results for barzolvolimab in chronic inducible urticaria.</li>
<li>Transcat, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRNS#NASDAQ">TRNS</a>) declined 11.2% to $120.00 following weak quarterly sales.</li>
<li>CrowdStrike Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) dipped 9.7% to $233.65 following reports indicating Delta Air Lines would seek compensation from the cybersecurity company for last week&#8217;s outage.</li>
<li>Rambus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBS#NASDAQ">RMBS</a>) shares dipped 9.3% to $50.61 following weak quarterly sales.</li>
<li>Corning Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLW#NYSE">GLW</a>) fell 8.7% to $38.99 following second-quarter results.</li>
<li>Lattice Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) shares fell 8.3% to $50.40 after the company reported worse-than-expected second-quarter financial results and issued weak third-quarter revenue guidance.</li>
<li>Ecolab Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>) declined 6.7% to $231.31 after the company reported worse-than-expected second-quarter sales results.</li>
<li>The Procter &amp; Gamble Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) fell 6.2% to $159.37 following a quarterly revenue miss.</li>
<li>Diageo plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEO#NYSE">DEO</a>) fell 5.5% to $124.30 after the company missed annual profit expectations.</li>
<li>Fresenius Medical Care AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMS#NYSE">FMS</a>) shares declined 4.5% to $19.45 following weak quarterly sales.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/40039797/top-3-health-care-stocks-you-may-want-to-dump-this-quarter">Top 3 Health Care Stocks You May Want To Dump This Quarter</a></li>
</ul>

Intraday Update

Movers

AMKR

ATPC

BIMI

BLMZ

CALC

CLDX

CNSP

CRWD

CVLT

EKSO

ENVB

FFIV

HAYW

HLIT

IMNN

INVO

ISPO

JBLU

JTAI

LSCC

LUMN

MBIN

NIPG

NVAX

ONEW

PCSA

PHAR

PYPL

RGEN

RMBS

SMRT

TLRY

TRNS

TWOU

VBIV

VRNS

VSEE

Why Merck Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 0.1% on Tuesday.
Shares of Lattice Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) fell sharply in today's pre-market trading after the company reported worse-than-expected second-quarter financial results and issued weak <a href="https://www.benzinga.com/news/earnings/24/07/40022763/lattice-semiconductor-stock-falls-on-worse-than-expected-q2-results">third-quarter revenue guidance</a>.
Lattice Semiconductor reported quarterly earnings of 23 cents per share, which missed the analyst consensus estimate of 24 cents per share. Quarterly sales came in at $124.076 million, which missed the analyst consensus estimate of $130.172 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Lattice Semiconductor shares tumbled 14.8% to $46.82 in the pre-market trading session.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>Symbotic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NASDAQ">SYM</a>) shares dipped 19.5% to $28.70 in pre-market trading after the company reported worse-than-expected third-quarter earnings results and issued fourth-quarter revenue guidance below estimates.</li>
<li>Woodward, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WWD#NASDAQ">WWD</a>) declined 10.5% to $164.01 in pre-market trading after the company reported mixed third-quarter financial results and lowered its FY24 revenue guidance below estimates.</li>
<li>Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) shares dipped 9.6% to $14.85 in pre-market trading after declining 4% on Monday.</li>
<li>Celldex Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) shares tumbled 8.6% to $38.33 in pre-market trading after reporting Phase 2 results for barzolvolimab in chronic inducible urticaria.</li>
<li>Diageo plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEO#NYSE">DEO</a>) declined 8.5% to $120.36 in pre-market trading after the company missed annual profit expectations.</li>
<li>Rambus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBS#NASDAQ">RMBS</a>) shares fell 7.8% to $51.50 in pre-market trading following weak quarterly sales.</li>
<li>Soho House &amp; Co Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHCO#NYSE">SHCO</a>) fell 7.3% to $4.80 in pre-market trading. Soho House &amp; Co will release its second-quarter financial results on Friday, Aug. 9.</li>
<li>Fitell Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTEL#NASDAQ">FTEL</a>) declined 6.8% to $14.67 in pre-market trading.</li>
<li>Amkor Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMKR#NASDAQ">AMKR</a>) shares fell 6.2% to $35.28 in pre-market trading after the company issued roughly in-line guidance.</li>
<li>Fresenius Medical Care AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMS#NYSE">FMS</a>) shares declined 5.7% to $19.20 in pre-market trading following weak quarterly sales.</li>
<li>CrowdStrike Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) shares declined 4.7% to $246.69 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/40009447/roblox-morgan-stanley-and-2-other-stocks-insiders-are-selling">Roblox, Morgan Stanley And 2 Other Stocks Insiders Are Selling</a></li>
</ul>

Pre-Market Outlook

FTEL

SHCO

Lattice Semiconductor Posts Weak Q2 Results, Joins Symbotic, Woodward And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

WIIM

Fresenius Medical Care shares are trading lower after the company reported mixed Q2 financial results.

Fresenius Medical Care Confirms Its Outlook For Fiscal 2024 And Expects Revenue To Grow By Low- To Mid-single Digit Percent Rate YoY, With Operating Income To Grow By Mid- To High-teens Percent Rate

Fresenius Medical Care Q2 2024 Adj. EPS €0.35 Beats €0.34 Estimate, Sales €4.766B Miss €4.812B Estimate

DaVita and Fresenius shares are trading lower following a report suggesting the FTC is investigating the companies.

Investors demanded more clarity from German healthcare group&nbsp;Fresenius SE&nbsp;regarding its intentions to relinquish strategic control over dialysis group&nbsp;Fresenius Medical Care AG&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMS#NYSE">FMS</a>).&nbsp;
The investors&#8217; call for transparency comes in the wake of Fresenius&#8217;s recent deconsolidation of Fresenius Medical Care, where the company still retains a 32% stake.
Fresenius Medical Care faced significant challenges during the COVID-19 pandemic, including a higher mortality rate among dialysis patients and a shortage of nursing staff.&nbsp;
&#8220;The volatility at Fresenius Medical Care seems&nbsp;to repeatedly overshadow the recent positive operating developments at Fresenius&nbsp;and is also deterring many potential shareholders from investing in Fresenius,&#8221; Reuters noted, citing Hendrik Schmidt, a corporate governance expert at fund manager DWS.
&#8220;Thus, despite the deconsolidation, the share price of Fresenius SE remains vulnerable to operational and strategic difficulties at Fresenius Medical Care,&#8221; Reuters noted.
These issues led to Fresenius Medical Care repeatedly missing the healthcare group&#8217;s annual targets. However, recent performance improvements suggest a potential turnaround for the dialysis specialist.
Michael Sen, who took over as CEO of Fresenius SE in 2022, has been actively pushing for the company&#8217;s realignment. His strategic initiatives have included divesting various peripheral businesses to streamline operations and focus on core areas. This realignment is part of Sen&#8217;s broader vision to strengthen the company&#8217;s position in&nbsp;the healthcare sector.
Fresenius Medical Care&#8217;s deconsolidation, executed by changing its legal structure at the end of November, is a&nbsp;key step in its restructuring efforts.&nbsp;
Despite this, investors are eager to understand&nbsp;the long-term strategic plans for&nbsp;Fresenius SE and Fresenius Medical Care, emphasizing the need for greater clarity on the dialysis group&#8217;s future direction.
Last week, Fresenius Medical Care reported first-quarter revenue of 4.73 billion euros, up 2%&nbsp;Y/Y&nbsp;(+5% organic), driven by Care Delivery and&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/05/n38664285/fresenius-medical-care-starts-the-year-with-strong-earnings-growth" rel="noreferrer noopener">Care Enablement segments</a>.
&#8220;We have started the year with a slightly more favorable operating income phasing than planned and confirm our financial outlook for the full year 2024, said Helen Giza, CEO of Fresenius Medical Care.
Price Action:&nbsp;FMS shares&nbsp;are&nbsp;up 0.78% at $21.93&nbsp;at last check&nbsp;Friday.
Photo: Shutterstock

Global

Fresenius SE's Future With Dialysis Company Unclear, Investors Seek Answers

Truist Securities analyst David Macdonald maintains Fresenius Medical Care (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMS#NYSE">FMS</a>) with a Hold and raises the price target from $21 to $24.

Truist Securities Maintains Hold on Fresenius Medical Care, Raises Price Target to $24

<h3>Gainers</h3>
<ul>
<li>FibroGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) shares rose 37.1% to $1.59 during Tuesday's pre-market session. The market value of their outstanding shares is at $158.1 million. The company's, Q1 earnings came out yesterday. </li>
<li>Envoy Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCH#NASDAQ">COCH</a>) stock moved upwards by 23.54% to $4.25. The company's market cap stands at $83.2 million. </li>
<li>iSpecimen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) shares rose 21.18% to $0.33. The company's market cap stands at $3.0 million. The company's, Q1 earnings came out today. </li>
<li>NovaBay Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NBY#AMEX">NBY</a>) shares moved upwards by 20.87% to $0.11. The company's market cap stands at $3.9 million. </li>
<li>GT Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTBP#NASDAQ">GTBP</a>) shares rose 19.25% to $3.84. The market value of their outstanding shares is at $5.3 million. </li>
<li>Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) stock increased by 18.39% to $2.51. The company's market cap stands at $475.3 million. As per the news, the Q1 earnings report came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) shares decreased by 16.5% to $2.02 during Tuesday's pre-market session. The company's market cap stands at $1.7 million. </li>
<li>Cellectis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLLS#NASDAQ">CLLS</a>) shares declined by 11.05% to $2.98. The company's market cap stands at $214.4 million. </li>
<li>Eledon Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELDN#NASDAQ">ELDN</a>) shares fell 9.43% to $2.21. The market value of their outstanding shares is at $54.8 million. </li>
<li>Fresenius Medical Care (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMS#NYSE">FMS</a>) stock fell 8.03% to $19.7. The company's market cap stands at $11.5 billion. </li>
<li>Madrigal Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDGL#NASDAQ">MDGL</a>) shares declined by 7.42% to $218.1. The market value of their outstanding shares is at $4.6 billion. The company's, Q1 earnings came out today. </li>
<li>Context Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTX#NASDAQ">CNTX</a>) shares declined by 7.31% to $1.65. The company's market cap stands at $26.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CLLS

CNTX

Envoy Medical, Inc. - Class A Common Stock

COCH

ELDN

ESPR

FGEN

GTBP

HSDT

ISPC

MDGL

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

U.S. stock futures were mostly higher this morning, with the Dow futures gaining around 80 points on Tuesday.
Shares of AudioCodes Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUDC#NASDAQ">AUDC</a>) fell sharply in today's pre-market trading after the company reported worse-than-expected <a href="https://www.benzinga.com/quote/AUDC/earnings">first-quarter financial results</a>.
AudioCodes posted adjusted earnings of 17 cents per share, missing market estimates of 23 cents per share. The company's quarterly sales came in at $60.076 million versus expectations of $62.452 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
AudioCodes shares dipped 11.3% to $10.10 in pre-market trading in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>Trupanion, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUP#NASDAQ">TRUP</a>) shares fell 13% to $20.68 in pre-market trading following first-quarter results.</li>
<li>Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) shares dipped 9.3% to $22.85 pre-market trading following soft revenue guidance.</li>
<li>Lucid Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) shares fell 8.5% to $2.79 in pre-market trading after the company reported mixed first-quarter financial results.</li>
<li>Beyond, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYON#NYSE">BYON</a>) fell 8.3% to $20.08 in pre-market trading following weaker-than-expected quarterly results.</li>
<li>Fresenius Medical Care AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMS#NYSE">FMS</a>) shares declined 7.9% to $19.73 in pre-market trading.</li>
<li>Bilibili Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BILI#NASDAQ">BILI</a>) shares fell 5.4% to $13.97 in pre-market trading.</li>
<li>Gold Fields Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFI#NYSE">GFI</a>) shares slipped 5.1% to $15.71 in pre-market trading.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/05/38661465/investor-optimism-decreases-slightly-but-dow-records-gains-for-4th-day">Investor Optimism Decreases Slightly, But Dow Records Gains For 4th Day</a>
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>

AUDC

BILI

BYON

LCID

PLTR

TRUP

AudioCodes Reports Downbeat Earnings, Joins Trupanion, Palantir Technologies And Other Big Stocks Moving Lower In Tuesday Pre-Market Session

U.S. stocks were higher, with the Nasdaq Composite gaining over 100 points on Monday.
Shares of Matterport, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTTR#NASDAQ">MTTR</a>) rose sharply <a href="https://www.benzinga.com/quote/MTTR/news">during Monday's session</a>.
CoStar Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSGP#NASDAQ">CSGP</a>) announced plans to acquire Matterport in a cash and stock transaction valued at $5.50 per share reflecting an estimated $1.6 billion value.
Matterport shares climbed 184% to $4.93 on Monday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Graphjet Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTI#NASDAQ">GTI</a>) surged 27.6% to $8.61. Graphjet Technology&#8217;s Tham Choi Kuen, CFO, announced the decision to resign due to health reasons, effective immediately.</li>
<li>Adlai Nortye Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANL#NASDAQ">ANL</a>) gained 12.1% to $13.90.</li>
<li>MicroStrategy Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) shares climbed 11.2% to $1,305.56 amid a rise in Bitcoin.</li>
<li>Sea Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SE#NYSE">SE</a>) surged 10.4% to $60.79 after B of A Securities upgraded the stock from Neutral to Buy and raised its price target from $62 to $70.</li>
<li>Ingevity Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGVT#NYSE">NGVT</a>) climbed 8.7% to $48.30. Jefferies analyst Daniel Rizzo upgraded Ingevity from Hold to Buy and raised the price target from $52 to $62.</li>
<li>KB Financial Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KB#NYSE">KB</a>) surged 8.2% to $50.01.</li>
<li>Riot Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>) gained 7.9% to $9.85 amid a rise in Bitcoin.</li>
<li>Guardant Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GH#NASDAQ">GH</a>) climbed 7.9% to $17.31. The Molecular and Clinical Genetics Panel of the U.S. FDA Medical Devices Advisory Committee is scheduled to review the premarket approval application for the company&#8217;s Shield&#x2122; blood test for colorectal cancer (CRC) screening on May 23, 2024.</li>
<li>Lexeo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXEO#NASDAQ">LXEO</a>) rose 6.7% to $12.86 as the company announced a license agreement to accelerate development of LX2006 for the treatment of friedreich ataxia cardiomyopathy.</li>
<li>Lexicon Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) gained 6.5% to $1.7550</li>
<li>Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) shares rose 6.5% to $224.72 amid a rise in Bitcoin.</li>
<li>Critical Metals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRML#NASDAQ">CRML</a>) gained 6.2% to $8.60.</li>
<li>Fresenius Medical Care AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMS#NYSE">FMS</a>) rose 5.4% to $20.60.</li>
</ul>
Read More: <a href="https://www.benzinga.com/news/24/04/38356135/wall-streets-most-accurate-analysts-views-on-3-defensive-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts&#8217; Views On 3 Defensive Stocks Delivering High-Dividend Yields</a>

COIN

CRML

CSGP

LXEO

LXRX

MSTR

MTTR

NGVT

RIOT

Matterport, Sea Limited, Ingevity And Other Big Stocks Moving Higher On Monday

Tuesday,&nbsp;Novo Nordisk A/S&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) released the headline results from the kidney outcomes trial, FLOW.
The trial achieved its primary endpoint by demonstrating a statistically significant and superior reduction in kidney disease progression as well as cardiovascular and kidney death of 24% for people treated with semaglutide <a href="https://www.benzinga.com/general/biotech/24/03/37478859/novo-nordisk-says-famed-diabetes-medicine-ozempic-reduces-risk-of-kidney-disease-progression-data" target="_blank" rel="noreferrer noopener">1.0 mg compared to placebo</a>. 
Stocks of kidney dialysis-focused DaVita Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVA#NYSE">DVA</a>), Fresenius Medical Care AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMS#NYSE">FMS</a>), and Baxter International Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>) shares fell sharply when Novo Nordisk stopped the semaglutide kidney outcomes trial FLOW based on early signs of <a href="https://www.benzinga.com/news/large-cap/23/10/35190991/whats-going-on-with-kidney-dialysis-provider-stocks-today" target="_blank" rel="noreferrer noopener">efficacy in October last year</a>.
Whereas, kidney dialysis stocks are trading higher today as Novo Nordisk&#8217;s popular diabetes drug, Ozempic, fell short of some expectations.
Citing J.P.Morgan analyst, Reuters noted, &#8220;We see 24% as at the low end of expectations &#8211; that is, there were some fears out there that the impact could have been higher,&#8221; adding that this could be contributing to the relief in Fresenius&#8217; shares.
DaVita and German competitor Fresenius have downplayed concerns regarding GLP-1 drugs like Ozempic and Wegovy, which exhibit significant advancements in treating obesity and diabetes. The emergence of these drugs has led to a contraction in the kidney care market.
In October, citing&nbsp;Citi&nbsp;analyst, Reuters noted that GLP-1 drugs could &#8220;potentially negatively impact&#8221; the size of the dialysis patient population over time.
Price Action: DVA shares are up 7.99% at $135.78, FMS stock is up 11.4% at $20.80, and BAX shares are up 1.88% at $43.30 on the last check Tuesday.
Image By Natalia Varlei On Shutterstock

Why Are Dialysis Provider Stocks Trading Higher On Tuesday?

In a report released on November 5, Oliver Reinberg from Kepler Capital maintained a Hold rating on Fresenius Medical Care AG & Co. KGaA (0H9X – Re...

Kepler Capital  Reaffirms Their Hold Rating on Fresenius Medical Care AG & Co. KGaA (0H9X)

Barclays raised the firm's price target on Fresenius Medical (FMS) to EUR 39 from EUR 38.50 and keeps an Equal Weight rating on the shares. Publish...

Fresenius Medical price target raised to EUR 39 from EUR 38.50 at Barclays

Assessing MedTech impact from potential China tariffs

In a report released today, Graham Doyle from UBS maintained a Hold rating on Fresenius Medical Care AG & Co. KGaA (0H9X – Research Report), with a...

UBS Keeps Their Hold Rating on Fresenius Medical Care AG & Co. KGaA (0H9X)

DaVita: Better Results Than Fresenius, But A 'Hold' Due To Valuation

Medtech shouldn't be greatly impacted by RFK Jr. at HHS, Wells Fargo says

Goldman Sachs analyst Richard Felton maintained a Buy rating on Fresenius Medical Care AG & Co. KGaA (0H9X – Research Report) today and set a price...

Fresenius Medical Care AG & Co. KGaA (0H9X) Gets a Buy from Goldman Sachs

Global companies with at least 50% U.S. revenue exposure as Trump eyes tariffs: BofA

Fresenius Medical's (FMS) heart and lung group has been awarded a national group purchasing agreement for Mechanical Circulatory Support with Premi...

Fresenius Medical's Novalung ECMO System selected by Premier

Barclays raised the firm's price target on Fresenius Medical (FMS) to EUR 41 from EUR 39 and keeps an Equal Weight rating on the shares. Published ...

Fresenius Medical price target raised to EUR 41 from EUR 39 at Barclays

ALGN

ARGX

BGNE

BRDCY

DXCM

FMCQF

FSNUF

FSNUY

FUJHY

GEHC

KWEB

LEGN

LNVGY

MASI

MCHI

NVST

SOLV

SVNDY

TNDM

UPRO

Press Releases

Fresenius Medical Care starts the year with strong earnings growth

Fresenius Medical Care Annual General Meeting: Company makes significant progress in its Transformation Efforts and confirms its ambitious 2024 Growth Targets

Fresenius Medical Care showcases leadership and innovation in kidney care disease at 61st European Renal Association (ERA) Congress 2024

Moody's and S&P change Fresenius Medical Care's rating outlook to stable

Commodities

Fresenius Medical Care takes next important step towards goal to reduce CO2 emissions in its operations

Fresenius Medical Care delivers continued operating income improvements in the second quarter of 2024

Fresenius Medical Care Grows Number of U.S. Patients Using Company's Home Hemodialysis Machines, Launches NxStage® Versi®HD with GuideMe Software

Fresenius Medical Care Showcases Research and Innovations in Kidney Care at American Society of Nephrology (ASN) Kidney Week 2024

Fresenius Medical Care reports strong operating income margin growth in the third quarter of 2024

Contracts

Fresenius Medical Care Awarded Mechanical Circulatory Support Agreement with Premier, Inc. for the Novalung® ECMO System

Comments

Fresenius Medical Care

Notizie

Ultime notizie per Fresenius Medical Care (NYSE:FMS) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO